Mark M. Kowalski
Chief Tech/Sci/R&D Officer at EUPRAXIA PHARMACEUTICALS INC.
Net worth: 25 920 $ as of 2024-03-30
Mark M. Kowalski active positions
Companies | Position | Start | End |
---|---|---|---|
EUPRAXIA PHARMACEUTICALS INC. | Chief Tech/Sci/R&D Officer | 2023-05-17 | - |
Career history of Mark M. Kowalski
Former positions of Mark M. Kowalski
Companies | Position | Start | End |
---|---|---|---|
SIERRA ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 2016-12-31 | 2022-03-09 |
ARBUTUS BIOPHARMA CORPORATION | Chief Tech/Sci/R&D Officer | 2013-08-11 | 2016-09-29 |
Viventia Bio, Inc.
Viventia Bio, Inc. BiotechnologyHealth Technology Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada. | Chief Tech/Sci/R&D Officer | - | - |
AAIPharma, Inc.
AAIPharma, Inc. Miscellaneous Commercial ServicesCommercial Services AAIPharma, Inc. provides product development services to the pharmaceutical, biotechnology and medical device industries. Its services include drug delivery technologies, contract manufacturing, clinical packaging and distribution and bioanalytical services. The company was founded in 1979 and is headquartered in Wilmington, NC. | Chief Tech/Sci/R&D Officer | - | - |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Chief Tech/Sci/R&D Officer | - | - |
General Counsel | - | - | |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Chief Tech/Sci/R&D Officer | 2011-01-16 | - |
General Counsel | 2011-01-16 | - |
Training of Mark M. Kowalski
Rutgers State University of New Jersey | Undergraduate Degree |
University of Kansas Medical School | Doctorate Degree |
Statistics
International
United States | 6 |
Canada | 5 |
Operational
Chief Tech/Sci/R&D Officer | 7 |
General Counsel | 2 |
Undergraduate Degree | 1 |
Sectoral
Health Technology | 7 |
Consumer Services | 3 |
Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 2 |
---|---|
ARBUTUS BIOPHARMA CORPORATION | Health Technology |
EUPRAXIA PHARMACEUTICALS INC. | Health Technology |
Private companies | 5 |
---|---|
AAIPharma, Inc.
AAIPharma, Inc. Miscellaneous Commercial ServicesCommercial Services AAIPharma, Inc. provides product development services to the pharmaceutical, biotechnology and medical device industries. Its services include drug delivery technologies, contract manufacturing, clinical packaging and distribution and bioanalytical services. The company was founded in 1979 and is headquartered in Wilmington, NC. | Commercial Services |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | Health Technology |
Viventia Biotech, Inc.
Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Health Technology |
Sierra Oncology, Inc.
Sierra Oncology, Inc. BiotechnologyHealth Technology Sierra Oncology, Inc. was a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focused on advanced targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded in May 2003 and is headquartered in San Mateo, CA. | Health Technology |
Viventia Bio, Inc.
Viventia Bio, Inc. BiotechnologyHealth Technology Viventia Bio, Inc. operates as a biologics oncology company, which focuses on designing, engineering, and developing targeted protein therapeutics. The company was founded by Leslie Lewis Dan in October 2012 and is headquartered in Winnipeg, Canada. | Health Technology |
- Stock Market
- Insiders
- Mark M. Kowalski
- Experience